Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronica: l’esperienza della ASL della provincia di Alessandria

Introduction Anemia represents one of the most frequent and debilitating disease associated with chronic kidney disease (CKD). If anemia is untreated, the quality of life is reduced and survival shortened. Epoetin (α o β) and darbepoetin-α are Erythropoietin Receptor Agonists (ERAs) indicated for the treatment of anemia in patients with CKD.